TCRX
TScan Therapeutics, Inc.
$1.07
+0.02 (+1.90%)
At close · Jul 7
Market Cap
$70.25M
Shares
65,350,817
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$10.33M
+266.7%
FY2025
Net Income
-$129.77M
-1.8%
FY2025
Operating Margin
-1315.38%
+3472.3pp
FY2025
Diluted EPS
-$1.00
+12.3%
FY2025
Operating Cash Flow
-$135.32M
-22.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| $9.14M | $10.33M | $2.82M | $21.05M | $13.54M | $10.14M | |
| $106.27M | $114.15M | $107.35M | $88.15M | $59.82M | $44.95M | |
| $31.57M | $31.99M | $30.29M | $26.35M | $20.35M | $13.83M | |
| — | $2.9M | $4.1M | $5.4M | $5.1M | $3.3M | |
| $137.84M | $146.14M | $137.64M | $114.51M | $80.17M | $58.78M | |
| -$128.7M | -$135.81M | -$134.82M | -$93.46M | -$66.64M | -$48.64M | |
| — | -1315.38% | -4787.68% | -444% | -492.32% | -479.65% | |
| — | -$132.91M | -$130.72M | -$88.06M | -$61.54M | -$45.34M | |
| $2.78M | $2.77M | $3.65M | $3.76M | $1.18M | — | |
| $4.4M | $6.05M | $7.32M | $4.24M | $415K | — | |
| — | $0 | — | — | — | — | |
| -$124.31M | -$129.77M | -$127.5M | -$89.22M | -$66.22M | -$48.63M | |
| — | -1256.81% | -4527.66% | -423.86% | -489.26% | -479.49% | |
| -$124.3M | -$129.82M | -$127.45M | — | — | — | |
| USD/shares | — | -$1.00 | -$1.14 | -$1.36 | -$2.75 | — |
| USD/shares | — | -$1.00 | -$1.14 | -$1.36 | -$2.75 | — |
| shares | — | 129.78M | 111.99M | 65.6M | 24.05M | 11.66M |
| shares | — | 129.78M | 111.99M | 65.6M | 24.05M | 11.66M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Reportable Segment | $10,325,000 | $2,816,000 | $21,049,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | 2024-12-31 | 2023-12-31 |
|---|---|---|
| Reportable Segment | -$134,821,000 | -$93,458,000 |
Operating Margin by Segment (%)
| Component | 2024-12-31 | 2023-12-31 |
|---|---|---|
| Reportable Segment | -4787.7% | -444% |